[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-350391-105":59,"doc-detail-350391-en":131},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":124,"head_meta":126,"extra_data":128,"updated_unix":130},105,"en","ferroptosis-as-a-therapeutic-vulnerability-in-arid1a-deficient-bladder-cancer","Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer","","ARID1A is frequently mutated in bladder cancer, but no targeted therapy exists for this molecular subset. The study identifies ferroptosis induction as a synthetic lethal strategy in ARID1A-deficient bladder cancer, showing that ARID1A loss disrupts the NRF2–SLC7A11–glutathione axis and causes redox imbalance. ARID1A knockdown depletes intracellular GSH, amplifies RSL-3–driven lipid peroxidation, and triggers cell death. Mechanistically, ARID1A regulates NRF2 transcription and SLC7A11, and restoring NRF2/SLC7A11 activity or GSH rescues sensitivity. In vivo, RSL-3 delays tumors and improves survival in Arid1a-deficient mouse models, and organoids from ARID1A-low tumors show heightened RSL-3 responsiveness.",{"@graph":69,"@context":123},[70,84,106],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/ferroptosis-as-a-therapeutic-vulnerability-in-arid1a-deficient-bladder-cancer/350391/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/ferroptosis-as-a-therapeutic-vulnerability-in-arid1a-deficient-bladder-cancer/350391.png","ImageObject",300,407,{"name":92,"@type":93},"eBook King","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-13","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":105},"InteractionCounter",{"@type":104},"ViewAction",13,{"@type":107,"mainEntity":108},"FAQPage",[109,115,119],{"name":110,"@type":111,"acceptedAnswer":112},"What therapeutic vulnerability is identified for ARID1A-deficient bladder cancer?","Question",{"text":113,"@type":114},"The study identifies ferroptosis induction as a synthetic lethal vulnerability in ARID1A-deficient bladder cancer, particularly through sensitivity to the ferroptosis inducer RSL-3.","Answer",{"name":116,"@type":111,"acceptedAnswer":117},"How does ARID1A loss affect ferroptosis sensitivity at the molecular level?",{"text":118,"@type":114},"ARID1A loss impairs the NRF2–SLC7A11–glutathione axis, leading to redox imbalance, GSH depletion, and increased lipid peroxidation, which drives ferroptosis.",{"name":120,"@type":111,"acceptedAnswer":121},"What evidence supports translational relevance beyond cell culture?",{"text":122,"@type":114},"RSL-3 treatment delays tumor progression, reduces muscle invasion, and improves survival in Arid1a-deficient mouse models, and ARID1A-low patient-derived organoids show heightened RSL-3 sensitivity.","https://schema.org",{"og:url":83,"og:type":125,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":127,"canonical":83},"index,follow",{"doc_id":129,"site_id":62},350391,1790639211,{"code":4,"msg":5,"data":132},{"doc_id":129,"user_id":133,"nickname":92,"user_avatar":134,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":135,"file_id":136,"file_url":137,"file_type":138,"file_size":139,"view_count":105,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":105,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962088006270,"https://ap-avatar.wpscdn.com/davatar_085a072bc5b1113ac321206ff7593b45","communications biology Article  \nA Nature Portfolio journal  \n[https://doi.org/10.1038/s42003-026-09998-w](https://doi.org/10.1038/s42003-026-09998-w)  \nFerroptosis as a therapeutic vulnerability in ARID1A-deﬁcient bladder cancer  \n Check for updates  \n\n| Mengxue Zhao1, Xuefeng Wang1, Xianbin Duan1, Chunyue Wu1, Rui Guo1, Yan Wen1, Jiaxin Liang1, Jie Zhou1, Xuefen Lei2, Shi Fu3, Haifeng Wang3, Cheng Peng 1 & Chunming Guo 1  |  |\n| --- | --- |\n| ARID1A is among the most frequently mutated genes in bladder cancer, yet no targeted therapy exists for this molecular subset. Here, we identify ferroptosis induction as a synthetic lethal strategy in ARID1A-deﬁcient bladder cancer. We found that ARID1A loss impaired the NRF2-SLC7A11-glutathione (GSH) axis, leading to redox imbalance and profound sensitivity to the ferroptosis inducer RSL-3 . In vitro, ARID1A knockdown depleted intracellular GSH and enhanced RSL-3-induced lipid peroxidation and cell death. Mechanistically, ARID1A directly regulated NRF2 transcription and its target SLC7A11, and restoring SLC7A11 or NRF2 activity or GSH levels rescued ferroptosis sensitivity. In vivo, RSL-3 treatment delayed tumor progression, reduced muscle invasion, and improved survival in two types of Arid1a-deﬁcient mouse models. Furthermore, patient-derived organoids from ARID1A-low human tumors exhibited heightened RSL-3 sensitivity rather than ARID1A-high tumor. Our ﬁndings establish ferroptosis as a targetable vulnerability in ARID1Adeﬁcient bladder cancer and provide a compelling rationale for clinical translation offerroptosis-based therapies in this molecularly deﬁned population. |  |\n| Bladder cancer is the fourth most commonly diagnosed malignancy in men worldwide1–3. Most cases are classiﬁed as urothelial carcinoma, with approximately 70% presenting as non-muscle-invasive bladder cancer (NMIBC; stages Ta–T1) and 30% as muscle-invasive bladder cancer (MIBC; stage ≥T2)3–6. Histologically, bladder neoplasia is categorized into carcinoma in situ (CIS), lamina propria-invasive bladder cancer (LIBC), and muscle-invasive bladder cancer (MIBC)7–9. Genomic studies have identiﬁed ARID1Aas one of the most frequently mutated genes in bladder cancer, with asigniﬁcantly higher mutation rate in MIBC than in NMIBC10, 11. ARID1Aencodesa core subunit of the SWI/SNF chromatin remodeling complex and is widely regarded as a tumor suppressor12–14. Mutations in ARID1A are present in approximately one-quarter of all bladder cancer patients, many of whom lack effective therapeutic options10, 15, 16.\u003Cbr>Tumor cells often exhibit loss or epigenetic silencing of tumor suppressor genes, a phenomenon that can extend to neighboring genes and create potential therapeutic vulnerabilities17, 18. This principle has been successfully exploited in metastatic uveal melanoma through synthetic lethal targeting of the CDS1-CDS2 gene pair19. In other cancer types, ARID1A deﬁciency has been associated with sensitivity to USP8-FGFR-STAT3 axis inhibition and metabolic reprogramming20. In bladder cancer, previous studies have identiﬁed vulnerabilities to PI3K and EZH2 inhibition in ARID1A-mutant contexts21. More recently, Krt5 | lineage-speciﬁc deletion of Arid1a was shown to promote translation elongation and accelerate tumorigenesis in mice; while translation inhibition selectively inhibited the growth of Arid1a-deﬁcient cells and ARID1A-low human tumors22. However, the identiﬁcation of additional or more potent vulnerabilities remains an open question in urological oncology.\u003Cbr>Although ARID1A-deﬁcient cancer cells have been reported to exhibit sensitization to pyroptosis23, this relationship has not been established in bladder cancer. Beyond pyroptosis, ferroptosis is a recently characterized form of regulated cell death driven by lipid peroxide accumulation and it has emerged as a promising therapeutic avenue24,25. Glutathione peroxidase 4 (GPX4) utilizes glutathione (GSH) to detoxify lipid peroxides under physiological condition","cbCaiuaPiJVZeEza","https://ap.wps.com/l/cbCaiuaPiJVZeEza","pdf",3460778,"English","# Background\n## Bladder cancer and ARID1A mutations\n## Synthetic lethality and regulated cell death\n# Ferroptosis biology and therapeutic rationale\n## GPX4–SLC7A11–glutathione axis\n## RSL-3/erastin and open question\n# Study findings\n## Synthetic lethal vulnerability in ARID1A-deficient models\n## Mechanism: NRF2 regulation and redox imbalance\n## Rescue experiments and functional validation\n# In vivo efficacy and translational relevance\n## Mouse model outcomes\n## Patient-derived organoid sensitivity","[{\"question\":\"What therapeutic vulnerability is identified for ARID1A-deficient bladder cancer?\",\"answer\":\"The study identifies ferroptosis induction as a synthetic lethal vulnerability in ARID1A-deficient bladder cancer, particularly through sensitivity to the ferroptosis inducer RSL-3.\"},{\"question\":\"How does ARID1A loss affect ferroptosis sensitivity at the molecular level?\",\"answer\":\"ARID1A loss impairs the NRF2–SLC7A11–glutathione axis, leading to redox imbalance, GSH depletion, and increased lipid peroxidation, which drives ferroptosis.\"},{\"question\":\"What evidence supports translational relevance beyond cell culture?\",\"answer\":\"RSL-3 treatment delays tumor progression, reduces muscle invasion, and improves survival in Arid1a-deficient mouse models, and ARID1A-low patient-derived organoids show heightened RSL-3 sensitivity.\"}]","Ferroptosis as a therapeutic vulnerability in ARID1A-deficient bladder cancer | PDF",1790088846,33,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7d0c92102332e88806788904621c69af.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ff15989a47fb5df7ae852edc1e6e9533.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d29264c39bcaa625d73b9559622577c6.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/efa33e79018e24ff87b04f45356f7bd6.webp",980,1301]